ProMIS Neurosciences Inc. (PMN): R&D Expense
$33.38M
Year ended 2025-12-31
$35.66M
Trailing 12 months to 2026-06-30
+27.5%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $33.38M | +213.8% | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | $10.64M | +34.9% | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | $7.88M | -51.0% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $16.09M | +247.7% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $4.63M | n/a | 2023-03-08, From 2021-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| ProMIS Neurosciences Inc. (PMN) | 2025-12-31 | $33.38M | +213.8% |
| Soligenix, Inc. (SNGX) | 2025-12-31 | $7.49M | +43.3% |
| Indaptus Therapeutics, Inc. (INDP) | 2025-12-31 | $9.34M | +28.8% |
| Kala Bio, Inc. (KALA) | 2025-12-31 | $18.78M | -15.0% |
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | $6.69M | +16.3% |
| Nanoviricides, Inc. (NNVC) | 2025-06-30 | $5.55M | +2.1% |
| FibroBiologics, Inc. (FBLG) | 2025-12-31 | $7.41M | +64.5% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $3.65M | -3.1% |
| MAIA Biotechnology, Inc. (MAIA) | 2025-12-31 | $453.7K | -95.5% |
Compare PMN, SNGX, INDP, KALA side by side · Screen every company in Pharmaceutical Preparations ↗